Showing results (1-10 of 91) with videos related to
Sort By:
Pageof 10
Cancer Biology & Therapy|March 15, 2024
Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypesIsil Ezgi Eryilmaz, Unal Egeli, Gulsah CecenerClinical and Experimental Pharmacology & Physiology|June 24, 2022
An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluatingIsil Ezgi Eryilmaz, Unal Egeli, Gulsah CecenerCancer Investigation|August 31, 2006
Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relativesUnal Egeli, Gulsah Cecener, Berrin Tunca, et al.Molecular Reproduction and Development|July 23, 2003
Frequency of recombinant and nonrecombinant products of pericentric inversion of chromosome 1 in sperm nuclei of carrier: by FISH techniqueTahsin Yakut, Hasan Acar, Unal Egeli, et al.Pharmaceutical Research|September 27, 2018
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast CancerGamze Guney Eskiler, Gulsah Cecener, Unal Egeli, et al.Journal of Biochemical and Molecular Toxicology|January 24, 2019
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profileGamze Guney Eskiler, Gulsah Cecener, Unal Egeli, et al.Cell Biology and Toxicology|September 3, 2016
An in vitro model for the development of acquired tamoxifen resistanceGamze Guney Eskiler, Gulsah Cecener, Berrin Tunca, et al.Journal of Cellular Physiology|February 5, 2020
Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancerGamze Guney Eskiler, Gulsah Cecener, Unal Egeli, et al.APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|April 27, 2018
Triple negative breast cancer: new therapeutic approaches and BRCA statusGamze Guney Eskiler, Gulsah Cecener, Unal Egeli, et al.Journal of Cancer Research and Therapeutics|May 6, 2023
The regulatory effect of cabazitaxel on epithelial-mesenchymal transition in metastatic prostate cancerIsil Ezgi Eryilmaz, Gamze Guney Eskiler, Unal Egeli, et al.Pageof 10